Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 506109 | NSE Symbol : GENESYS | ISIN : INE727B01026 | Industry : Computers - Software - Medium / Small |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
20-Mar-2025	20-Mar-2025	Quarterly Results	The Board of Directors of the Company in its meeting held today, March 20, 2025 inter alia approved the Unaudited Interim Condensed Consolidated Financial Statements for the nine months period ended December 31, 2024 along with the limited review report issued thereunder. This refers to our disclosure dated March 20, 2025 under Regulation 30 of SEBI (LODR) Regulations, 2015 filed with the exchange along with the Unaudited Interim Condensed Consolidated Financial Statements for the nine months period ended December 31, 2024. In this regard, please note that the Company inadvertently mentioned ''authorised capital as at December 31, 2024'' as 'Rs. 2,550.00 lakh' at note no. 7 of the Condensed Financial Statements instead of 'Rs. 2,725.00 lakh'. (As Per BSE Announcement Dated on: 25/03/2025)
11-Feb-2025	14-Feb-2025	Quarterly Results	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve This is to inform you that pursuant to Regulation 29 and other applicable provisions of SEBI (LODR) Regulations 2015 a meeting of the Board of Directors of the Company is scheduled to be held on February 14 2025 to consider and approve the following: a. the Un-audited financial results for the quarter ended December 31 2024. b. Proposal for raising of funds in one or more tranches by way of issuance of equity shares convertible securities debts issue or any other instrument or securities through qualified institutional placement private placements preferential issue or any other permissible modes and / or such other methods or combinations thereof in accordance with the Companies Act 2013 read with the rules notified thereunder and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 or under the applicable laws subject to such statutory approvals as may be required. c. Convening an Extraordinary General meeting The Board of directors at its meeting held on February 14, 2025 considered and approved un-audited financial results for the quarter ended 31st dec 2024 and enabling resolution for fund raising through QIP and approval of conveying EGM (As Per Bse Announcement Dated on 14.02.2025)
22-Oct-2024	28-Oct-2024	Quarterly Results	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve Pursuant to the provisions under Regulation 29 of SEBI (Listing Obligations and The Board of Directors of the Company at their meeting held today inter alia considered and approved Un-audited financial results (standalone and consolidated for the quarter and half year ended 30th September 2024. Enclosed financial Results and limited review report (As per BSE Announcement Date : 28/10/2024)
08-Aug-2024	14-Aug-2024	Quarterly Results	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve GENESYS INTERNATIONAL CORPORATION LTD. has informed BSE that a meeting of the Board of Directors of the Company will be held at registered office on Wednesday August 14 2024 to inter alia consider and approve the Un-audited Financial Results (standalone and consolidated) for the quarter ended June 30 2024. The Board of Directors at their meeting held today has inter alia considered and approved Un-audited Financial results (standalone and consolidated) for quarter ended June 30, 2024 (As Per Bse Announcement Dated on 14.08.2024)
24-May-2024	30-May-2024	Accounts	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company will be held at registered office on Thursday May 30 2024 to inter alia consider and approve the audited Financial results (standalone and consolidated) for the quarter and financial year ended March 31 2024. In compliance with the provisions of Regulation 30 and 33 of SEBI (LODR) Reg, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today has inter alia considered and approved following 1. Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended March 31, 2024 along with the statement of Assets and Liabilities 2. Appointment of M/s Roy Jacob & Co., Company Secretaries as the Secretarial Auditors of the Company for the financial year 2024-25. The Board of Directors at its meeting held today has appointed M/s. Roy Jacob & Co., Company Secretaries as the Secretarial Auditor of the Company for the financial year 2024-25. (As Per BSE Announcement Dated on 30.05.2024)
08-Feb-2024	14-Feb-2024	Quarterly Results	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Meeting of the Board of Directors of the Company will be held on Wednesday February 14 2024 to inter alia consider and approve the un-audited financial results (standalone and consolidated) for the quarter ended December 31 2023. The Board of Directors at their meeting held today i.e. February 14, 2024 has inter alia considered and approved the unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2023 along with limited review report. (As Per BSE Announcement Dated on: 14/02/2024)
12-Jan-2024	12-Jan-2024	Conversion	The Board of Directors at its meeting held today made an allotment of 16,23,490 equity shares pursuant to conversion of 16,23,490 warrants
27-Oct-2023	03-Nov-2023	Quarterly Results	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2023 inter alia to consider and approve Pursuant to the provisions under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and other applicable provisions rules and regulations if any this is to inform you that a meeting of the Board of Directors of the Company will be held on Friday November 03 2023 to inter alia consider and approve the un-audited financial results (standalone and consolidated) for the quarter and half year ended September 30 2023. The Board of Directors at their meeting held today has inter alia considered and approved Unaudited Financials Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2023 along with Limited Review Report for the quarter ended September 30, 2023. (As per BSE Announcement Dated on 03/11/2023)
31-Aug-2023	31-Aug-2023	AGM	In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held on August 31, 2023 has inter alia considered and approved following:- Kindly refer the attachment for further details. The register of members and Share Transfer Book of the Company will remain closed from Friday, September 22, 2023 to Thursday 28, 2023 (both days inclusive) for the purpose of 41st Annual General Meeting. (As Per BSE Announcement Dated on 01/09/2023)
08-Aug-2023	14-Aug-2023	Quarterly Results	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve Pursuant to the provisions under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and other applicable provisions rules and regulations if any this is to inform you that a meeting of the Board of Directors of the Company will be held on Monday August 14 2023 to inter alia consider and approve the un-audited financial results (standalone and consolidated) for the quarter ended June 30 2023. The Board of Directors of the Company, at their meeting held today has inter alia considered and approved Un-audited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2023 along with Limited Review Report for the quarter ended June 30, 2023 The meeting of Board commenced at 7.15 p.m. and concluded at 9.20 p.m. (As Per BSE Announcement Dated on 14.08.2023)
24-May-2023	30-May-2023	Accounts	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve Pursuant to the provisions under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and other applicable provisions rules and regulations if any this is to inform you that a meeting of the Board of Directors of the Company will be held at registered office on Tuesday May 30 2023 to inter alia consider and approve the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31 2023. In compliance with the Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached the Statement of Deviation or Variation or Utilization of funds raised through Preferential Issue by the Company for the quarter and financial year ended March 31, 2023 as reviewed by the Audit Committee. (As Per BSE Announcement Dated on 30.05.2023)
08-Feb-2023	14-Feb-2023	Quarterly Results	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Pursuant to the provisions under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and other applicable provisions rules and regulations if any this is to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday February 14 2023 to inter alia consider and approve the un-audited financial results (standalone and consolidated) for the quarter and nine months ended December 31 2022 In compliance with the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today, February 14, 2023 has inter alia considered and approved the following: i. Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022. Copies of the following enclosed as Annexure- I Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022; Limited Review Report of the Statutory Auditors on aforesaid results. The meeting of Board commenced at 5.00 p.m. and concluded at 6.15 p.m. In compliance with the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today, February 14, 2023, has inter alia considered and approved the following: i. Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022. Copies of the following enclosed as Annexure- I Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022; Limited Review Report of the Statutory Auditors on aforesaid results. The meeting of Board commenced at 5.00 p.m. and concluded at 6.15 p.m. (As Per BSE Announcement Dated on 14.02.2023)
11-Feb-2023	11-Feb-2023	Conversion	We hereby inform you that the Board of Directors of at their meeting held today i.e. February 11, 2023 has today allotted 7,50,000 equity shares of face value of Rs. 5/- each to Ms. Elizabeth Mathew. In terms of issue of Warrants, Ms. Elizabeth Mathew -non promoter has exercised the option of conversion of 7,50,000 Warrant into equity shares and the Company upon receipt of 75% of the balance money on said Warrants, has today allotted 7,50,000 equity shares of face value of Rs. 5/- each to Ms. Elizabeth Mathew.
15-Dec-2022	19-Dec-2022	Scheme of Amalgamation	This is to inform you that the meeting of the Board of Directors of the Company will beheld on 19th December, 2022, to consider and approve the scheme of amalgamation /merger of Virtual World Spatial Technologies Private Limited (VWSTPL) a whollyowned subsidiary, ('Transferor Company'), with Genesys International CorporationLimited (GICL) ('Transferee Company'As per the Company Code of Conduct framed under the SEBI (Prohibition of InsiderTrading) Regulations, 2015, the trading window for dealing in securities of the Companyshall remain closed for all Designated Persons and their immediate Relatives fromDecember 16 2022 till the expiry of 48 hours after outcome of the Board meeting isdeclared. The Board of Directors of the Company in its meeting held today has approved the Scheme of Amalgamation ('Scheme') for merger of Virtual World Spatial Technologies Private Limited (VWSTPL) (''Transferor Company'') with Genesys International Corporation Limited (GICL) (''Transferee Company''), pursuant to Section 230 to 232 of the Companies Act, 2013. VWSTPL is a wholly-owned subsidiary of the Company. The Scheme is subject to necessary statutory and regulatory approvals including the approvals of National Company Law Tribunal. The Scheme will be filed with the Stock Exchange as per applicable provisions of Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Disclosure pursuant to SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015 is provided in Annexure - I (As per BSE Announcement Dated on 19/12/2022)
08-Nov-2022	14-Nov-2022	Quarterly Results	GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve the un-audited financial results (standalone and consolidated) for the quarter and half year ended September 30 2022. In compliance with the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today, November 14, 2022 has inter alia considered and approved the following: i. Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2022. Copies of the following enclosed as Annexure- I Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2022; Limited Review Report of the Statutory Auditors on aforesaid results. The meeting of Board commenced at 5.30 p.m. and concluded at 6.45 p.m. (As Per BSE Announcement Dated on 14/11/2022) We are enclosing herewith the copy of Standalone and Consolidated un-audited financial results of the Company for the quarter and half year ended September 30, 2022 as published in the Newspaper - The Free Press Journal (English) and Navshakti (Marathi) on Wednesday, November 16, 2022 Request you to take the same on records. (As Per BSE Announcement Dated on 16/11/2022)

1 2 3

LOGIN HERE

Genesys International Corporation Ltd

Board Meeting